Cardior
AcquiredAt the pulse of heart diseases
Hanover, Germany · Founded 2016 · $92.1M raised
- Headquarters
- Hanover
- Founded
- 2016
- Business Model
- B2B
- Website
- cardior.de
- Total Funding
- $92.1M
- Last Round
- $74.6M Series BAug 2021
- Rounds
- 2
- Acquisition Date
- Mar 2024
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart, including heart failure. Its therapeutic approach uses distinctive non-coding RNAs as an innovative platform to address the root causes of cardiac dysfunction, with lead compound CDR132L in phase 2 trials. Novo Nordisk agreed to acquire Cardior in March 2024 for up to €1.025 billion.
Summary
Cardior is a Biotech company based in Hanover, Germany, founded in 2016. It has raised $92.1M in total across 2 rounds, most recently a $74.6M Series B round in Aug 2021. Investors include Inkef, LSP Life Sciences Partners and Bristol Myers Squibb.
Funding & Exit History
Mar 2024
Sign up to see all 3 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/cardior"><img src="https://indexed.vc/api/badge/company/cardior" alt="Cardior on Indexed.vc" width="260" height="76" /></a>